Not only pricing, but if Zantrene was approved for AML and made available as a single agent, wouldn't that effectively prevent altogether or at least greatly reduce the appeal of any licensing deals?
It would seem to me that there wouldn't be a lot of value for anyone to license Zantrene and develop a combination to sell as a high value product, extend patent life of their existing drugs, etc. if that could be effectively bypassed by buying the drugs separately and then using them together.
As I understand it, once a drug is approved for a single indication there isn't much that could be done to prevent it being used off label in this manner.
The exception to this could perhaps be the different formulations of Zantrene where the IV formulation may for example be kept for licensing while getting approval for the original formulation.
Ann: Race continues Board renewal - appoints new Chair, page-99
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.73 |
Change
0.170(10.9%) |
Mkt cap ! $294.7M | |||
| Open | High | Low | Value | Volume |
| $1.57 | $1.73 | $1.57 | $550.9K | 332.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | $1.71 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.73 | 999 | 1 |
View Market Depth
| Last trade - 16.10pm 26/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |